Samir Sunil Parekh

The paper integrates coding and noncoding genome annotations to improve transcriptomic analysis, identifying clinically relevant noncoding RNAs in multiple myeloma.

This study uses spatial and single-cell transcriptomics to identify niche-specific signaling programs in multiple myeloma that drive progression and immunosuppression.

This study shows that affinity-matured CD72-targeting nanobody CAR T-cells improve in vitro efficacy against CD72-low tumors but show limited in vivo benefit, while CD72 expression remains stable after CD19 resistance in B-cell malignancies.

Structure-optimized CD27-based CAR-T cells targeting CD70 show >80-fold improved expansion in vivo and offer a potential therapy for high-risk multiple myeloma patients.

The paper identifies a three-gene expression signature that predicts response to selinexor in multiple myeloma and glioblastoma.

This study identifies subtype-specific and co-occurring genetic alterations across major B-NHL subtypes using targeted sequencing of 380 genes in 685 tumors.

The paper shows ADAR1 drives Multiple Myeloma progression by editing RNA and causing DNA mutations at editing sites.